Aptol Pharma ApS: Financial statements 2023
CVR: 39308967
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Aptol Pharma ApS (CVR 39308967) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 414,462 and a net result of DKK 307,979 compared with DKK -334,362 the year before. Equity in the 2023 report amounted to DKK -9,047. The company had 1 employee in the financial year.
- Gross Profit
- DKK 414,462
- Profit/Loss
- DKK 307,979
- Equity
- DKK -9,047
- Total Assets
- DKK 163,435
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 414 t. | 308 t. | -9 t. | 1 |
| 2022 | - | -422 t. | -334 t. | -317 t. | - |
| 2021 | 0 | 0 | 0 | 50 t. | - |
| 2020 | 0 | -137 t. | -2 t. | 50 t. | - |
| 2019 | 0 | -102 t. | -2 t. | 50 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 27, 2023, Peter Andreas Nicolai Reumert Wagtmann has joined the board of directors of Aptol Pharma ApS.
As of August 21, 2023, Anders Dyhr Dombernowsky-Toft has joined the board of directors of Aptol Pharma ApS.
Aptol Pharma ApS has published its annual report for 2022. Gross profit came to DKK -421,544, and the net result was DKK -334,362.
About Aptol Pharma ApS
Aptol Pharma ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company is under bankruptcy. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include ADT HOLDING ApS, Tue Wenzel Kragstrup and Peter Andreas Nicolai Reumert Wagtmann. According to the 2024 annual report, the company had an average of 1 employee. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity in the 2024 report amounted to DKK -140,336.